A non biologic PCSK9 inhibitor could be a game changer! www.nytimes.com/2025/11/08/h...
New Pill From Merck Could Slash Cholesterol Levels, Trials Show
www.nytimes.com
November 9, 2025 at 1:54 PM
A non biologic PCSK9 inhibitor could be a game changer! www.nytimes.com/2025/11/08/h...
PCSK9 and peripheral #vascular outcomes in #diabetic patients:
👀Read our #interview 💬with the lead authors Federico Biscetti , Maria Margherita Rando and Andrea Flex
Read full article here ➡️ thieme-connect.de/products/ejo...
www.linkedin.com/pulse/pcsk9-...
👀Read our #interview 💬with the lead authors Federico Biscetti , Maria Margherita Rando and Andrea Flex
Read full article here ➡️ thieme-connect.de/products/ejo...
www.linkedin.com/pulse/pcsk9-...
PCSK9 and peripheral vascular outcomes in diabetic patients
THROMBOSIS AND HAEMOSTASIS: Why did you (and your colleagues) write this paper? What was its main purpose? Federico Biscetti, Maria Margherita Rando and Andrea Flex: We aimed to investigate the role o...
www.linkedin.com
October 23, 2025 at 9:22 AM
PCSK9 and peripheral #vascular outcomes in #diabetic patients:
👀Read our #interview 💬with the lead authors Federico Biscetti , Maria Margherita Rando and Andrea Flex
Read full article here ➡️ thieme-connect.de/products/ejo...
www.linkedin.com/pulse/pcsk9-...
👀Read our #interview 💬with the lead authors Federico Biscetti , Maria Margherita Rando and Andrea Flex
Read full article here ➡️ thieme-connect.de/products/ejo...
www.linkedin.com/pulse/pcsk9-...
New pre-print: "PCSK9 and breast cancer survival: a Mendelian Randomization study" www.medrxiv.org/content/10.1... led by Janne Pott. Brief thread:
PCSK9 and breast cancer survival: a Mendelian Randomization study
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is well known for its causal effects on the lipid metabolism. A recent study identified an association between rs562556 within PCSK9 a...
www.medrxiv.org
October 7, 2025 at 8:59 AM
New pre-print: "PCSK9 and breast cancer survival: a Mendelian Randomization study" www.medrxiv.org/content/10.1... led by Janne Pott. Brief thread:
📣Preprint alert - a tricky one, as there are no significant results (and we all know null-results are hard to publish)
Do PCSK9 levels affect survival in breast cancer patients?
We tried to replicate findings in cell lines and mouse model using 3 Mendelian Randomization approaches, but failed.
Do PCSK9 levels affect survival in breast cancer patients?
We tried to replicate findings in cell lines and mouse model using 3 Mendelian Randomization approaches, but failed.
PCSK9 and breast cancer survival: a Mendelian Randomization study https://www.medrxiv.org/content/10.1101/2025.10.03.25337270v1
October 6, 2025 at 4:50 PM
📣Preprint alert - a tricky one, as there are no significant results (and we all know null-results are hard to publish)
Do PCSK9 levels affect survival in breast cancer patients?
We tried to replicate findings in cell lines and mouse model using 3 Mendelian Randomization approaches, but failed.
Do PCSK9 levels affect survival in breast cancer patients?
We tried to replicate findings in cell lines and mouse model using 3 Mendelian Randomization approaches, but failed.
It can be hard to start new meds AFTER a patient leaves the hospital following and ACS event. Maybe we should consider starting the PCSK9 inhibitors during the index hospital stay. HOW to implement evidence-based therapies is a critical area to study
January 25, 2025 at 1:57 PM
It can be hard to start new meds AFTER a patient leaves the hospital following and ACS event. Maybe we should consider starting the PCSK9 inhibitors during the index hospital stay. HOW to implement evidence-based therapies is a critical area to study
LucidQuest Views >>> Cardiovascular Weekly News – June 12th 2025 #News #AFib #PCSK9 #ValveTherapy #EMSDisparities Comment below!
Cardiovascular Weekly News – June 12th 2025
🫀 Cardiovascular Update: CABG Boosts Survival, Polymer Valve Approved, PCSK9 Pill Succeeds and More From revolutionary valves to powerful […]
The post Cardiovascular Weekly News – June 12th 2025 appeared first on LucidQuest Ventures.
dlvr.it
June 12, 2025 at 9:23 AM
LucidQuest Views >>> Cardiovascular Weekly News – June 12th 2025 #News #AFib #PCSK9 #ValveTherapy #EMSDisparities Comment below!
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer @nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
May 21, 2025 at 8:19 PM
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer @nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Farmaci, riduzione significativa del colesterolo cattivo con nuovo inibitore orale di Pcsk9 ... LEGGI TUTTO #colesterolo #salute #farmaci #pcsk9 #trattamento
Farmaci, riduzione significativa del colesterolo cattivo con nuovo inibitore orale di Pcsk9
(Adnkronos) - Il farmaco sperimentale AZD0780 riduce in maniera statisticamente significativa il colesterolo legato alle lipoproteine a bassa densità (Lld-c) quando somministrato come trattamento aggiuntivo alla terapia standard con st...
dlvr.it
April 10, 2025 at 3:20 PM
Farmaci, riduzione significativa del colesterolo cattivo con nuovo inibitore orale di Pcsk9 ... LEGGI TUTTO #colesterolo #salute #farmaci #pcsk9 #trattamento
I have not, but if the results look bad (like if my score is >100 or something), I will ask for them. One of my colleagues (not South Asian, but also has terrible family history) got all this done and is now on a max dose statin and a PCSK9 inhibitor, and just couple of years older than me
February 2, 2025 at 5:34 PM
I have not, but if the results look bad (like if my score is >100 or something), I will ask for them. One of my colleagues (not South Asian, but also has terrible family history) got all this done and is now on a max dose statin and a PCSK9 inhibitor, and just couple of years older than me
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer - Nature
PCSK9 regulates low density lipoprotein-cholesterol import and determines organ preference of metastatic pancreatic ductal adenocarcinoma, with PCSK9-low cells metastasizing to the liver and PCSK9-hig...
www.nature.com
May 21, 2025 at 7:35 PM
PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer
www.nature.com/articles/s41...
www.nature.com/articles/s41...
#Yoltech with #China investigator-initiated n=6 #PCSK9 base editor data.
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
/PRNewswire/ -- YolTech Therapeutics Co.,Ltd, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic...
www.prnewswire.com
April 28, 2025 at 12:00 PM
#Yoltech with #China investigator-initiated n=6 #PCSK9 base editor data.
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Very similar approach to $verv, sees 50%LDLc lowering, but 50% with 'mild' liver enzme elevations.
www.prnewswire.com/news-release...
Thoughts on this? >> Regeneron defeats Amgen in PCSK9 case; 2 cell therapy
biotechs cut staff - BioPharma Dive >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #biotech #pharmaceutical
biotechs cut staff - BioPharma Dive >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #biotech #pharmaceutical
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy
biotechs cut staff - BioPharma Dive
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff BioPharma Dive
dlvr.it
May 16, 2025 at 4:00 PM
Thoughts on this? >> Regeneron defeats Amgen in PCSK9 case; 2 cell therapy
biotechs cut staff - BioPharma Dive >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #biotech #pharmaceutical
biotechs cut staff - BioPharma Dive >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #competitivemarketing #pharma #biotech #pharmaceutical
First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease
(MedPage Today) -- The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool of…
(MedPage Today) -- The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool of…
First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease
(MedPage Today) -- The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool of adults at increased... Source link
n24usa.com
August 26, 2025 at 8:22 AM
First PCSK9 Inhibitor Approved for Blanket Prevention of Heart Disease
(MedPage Today) -- The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool of…
(MedPage Today) -- The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool of…
Patients may better reach LDL cholesterol goals when PCSK9 inhibitors are given in-hospital after interventions. Despite some barriers to use, "making sure that patients get the medications that are indicated by the guidelines is essential,” says Leandro Slipczuk. www.tctmd.com/news/good-ld...
Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions
By beginning in hospital, researchers hope to kickstart LDL-lowering with a drug class that has been difficult to access.
www.tctmd.com
September 29, 2025 at 3:31 PM
Patients may better reach LDL cholesterol goals when PCSK9 inhibitors are given in-hospital after interventions. Despite some barriers to use, "making sure that patients get the medications that are indicated by the guidelines is essential,” says Leandro Slipczuk. www.tctmd.com/news/good-ld...
Our human PCSK9-targeting epigenetic editor is fully cross-reactive against cyno PCSK9, & we demonstrated that a single administration led to rapid and sustained, 90% reduction of PCSK9 protein, resulting in a clinically meaningful 70% reduction in LDL-C in non-human primates
7/9
7/9
February 10, 2025 at 2:05 PM
Our human PCSK9-targeting epigenetic editor is fully cross-reactive against cyno PCSK9, & we demonstrated that a single administration led to rapid and sustained, 90% reduction of PCSK9 protein, resulting in a clinically meaningful 70% reduction in LDL-C in non-human primates
7/9
7/9
Hyperlipidemia in hypothyroidism is both mediated by low T3 and high TSH
T3
🫀⬇️FFA beta-oxidation
🫀⬇️CYP7A1, leading to impaired cholesterol clearance
🫀⬇️Lipoprotein Lipase, decreasing hydrolysis of VLDL
TSH
🫀⬇️CYP7A1
🫀⬆️PCSK9
🫀⬆️HMG CoA reductase
🫀⬆️Hormone-Sensitive lipase
T3
🫀⬇️FFA beta-oxidation
🫀⬇️CYP7A1, leading to impaired cholesterol clearance
🫀⬇️Lipoprotein Lipase, decreasing hydrolysis of VLDL
TSH
🫀⬇️CYP7A1
🫀⬆️PCSK9
🫀⬆️HMG CoA reductase
🫀⬆️Hormone-Sensitive lipase
January 10, 2025 at 6:08 PM
Hyperlipidemia in hypothyroidism is both mediated by low T3 and high TSH
T3
🫀⬇️FFA beta-oxidation
🫀⬇️CYP7A1, leading to impaired cholesterol clearance
🫀⬇️Lipoprotein Lipase, decreasing hydrolysis of VLDL
TSH
🫀⬇️CYP7A1
🫀⬆️PCSK9
🫀⬆️HMG CoA reductase
🫀⬆️Hormone-Sensitive lipase
T3
🫀⬇️FFA beta-oxidation
🫀⬇️CYP7A1, leading to impaired cholesterol clearance
🫀⬇️Lipoprotein Lipase, decreasing hydrolysis of VLDL
TSH
🫀⬇️CYP7A1
🫀⬆️PCSK9
🫀⬆️HMG CoA reductase
🫀⬆️Hormone-Sensitive lipase
Association of PCSK9 inhibitors with bone disease: A comprehensive drug-target Mendelian randomization study https://www.medrxiv.org/content/10.1101/2025.03.09.25323603v1
March 13, 2025 at 9:41 AM
Association of PCSK9 inhibitors with bone disease: A comprehensive drug-target Mendelian randomization study https://www.medrxiv.org/content/10.1101/2025.03.09.25323603v1
#VERV Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
https://www.stocktitan.net/news/VERV/verve-therapeutics-announces-positive-initial-data-from-the-heart-2-efs4brr1eoj2.html
https://www.stocktitan.net/news/VERV/verve-therapeutics-announces-positive-initial-data-from-the-heart-2-efs4brr1eoj2.html
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Verve Therapeutics has announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, a single-dose base editing treatment targeting PCSK9 for cardiovascular disease. The trial included 14 participants with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).Key findings across three dose cohorts (0.3, 0.45, and 0.6 mg/kg) showed:Mean LDL-C reduction of 53% and maximum reduction of 69% in the 0.6 mg/kg cohortDose-dependent decreases in blood PCSK9 protein levelsNo treatment-related serious adverse eventsNo clinically significant changes in ALT or plateletsThe company plans to announce final dose escalation data in H2 2025, initiate Phase 2 trials, and receive Eli Lilly's decision on their PCSK9 program opt-in. Current funding is expected to last until mid-2027.
www.stocktitan.net
April 14, 2025 at 11:00 AM
#VERV Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
https://www.stocktitan.net/news/VERV/verve-therapeutics-announces-positive-initial-data-from-the-heart-2-efs4brr1eoj2.html
https://www.stocktitan.net/news/VERV/verve-therapeutics-announces-positive-initial-data-from-the-heart-2-efs4brr1eoj2.html
Concrete example of how inclusion of diverse research participants in biomedical research studies drives impactful discoveries: Genetic analysis identified PCSK9 as a drug target to lower LDL-C and led to successful development of novel drug. But did you know that diversity fueled this discovery?
April 16, 2025 at 3:42 PM
Concrete example of how inclusion of diverse research participants in biomedical research studies drives impactful discoveries: Genetic analysis identified PCSK9 as a drug target to lower LDL-C and led to successful development of novel drug. But did you know that diversity fueled this discovery?
PCSK9 and breast cancer survival: a Mendelian Randomization study https://www.medrxiv.org/content/10.1101/2025.10.03.25337270v1
October 5, 2025 at 11:27 PM
PCSK9 and breast cancer survival: a Mendelian Randomization study https://www.medrxiv.org/content/10.1101/2025.10.03.25337270v1
Though my ApoB is concerning, there could be a lot of reasons for that including a genetic mutation that affects my Pcsk9 levels (fun stuff)
February 12, 2025 at 5:33 PM
Though my ApoB is concerning, there could be a lot of reasons for that including a genetic mutation that affects my Pcsk9 levels (fun stuff)
Yes, the antibody inactivating PCSK9 is a powerful medicine against FH, great to know that it's working for your family🙏, and atherosclerotic vascular diseases. This study extends anti PCSK9 appraoch to AAA, another atherosclerotuc complications. But the authors didn't test the antibody formula🙂
November 27, 2024 at 8:36 PM
Yes, the antibody inactivating PCSK9 is a powerful medicine against FH, great to know that it's working for your family🙏, and atherosclerotic vascular diseases. This study extends anti PCSK9 appraoch to AAA, another atherosclerotuc complications. But the authors didn't test the antibody formula🙂
Geranylgeranyl Isoprenoids and Hepatic Rap1a Regulate Basal and Statin-Induced Expression of PCSK9 https://www.biorxiv.org/content/10.1101/2023.10.23.563509v1
Geranylgeranyl Isoprenoids and Hepatic Rap1a Regulate Basal and Statin-Induced Expression of PCSK9 https://www.biorxiv.org/content/10.1101/2023.10.23.563509v1
Low-density lipoprotein cholesterol (LDL-C) lowering is the main goal of atherosclerotic cardiovascu
www.biorxiv.org
October 24, 2023 at 3:28 AM
Geranylgeranyl Isoprenoids and Hepatic Rap1a Regulate Basal and Statin-Induced Expression of PCSK9 https://www.biorxiv.org/content/10.1101/2023.10.23.563509v1
A genetic variant in PCSK9 found in 70% of white women has been linked to breast cancer survival and metastasis. It increases PCSK9’s binding and suppression of LRP1 in tumours, driving metastasis. But here’s the hopeful part: blocking PCSK9 can improve outcomes.
www.cell.com/cell/abstrac...
www.cell.com/cell/abstrac...
A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor
Characterization of a common germline variant in PCSK9 unveils a hereditary basis underlying breast cancer metastasis and suggests that PCSK9 inhibition therapy could be a promising strategy for breast cancer metastasis prevention.
www.cell.com
December 10, 2024 at 11:40 AM
A genetic variant in PCSK9 found in 70% of white women has been linked to breast cancer survival and metastasis. It increases PCSK9’s binding and suppression of LRP1 in tumours, driving metastasis. But here’s the hopeful part: blocking PCSK9 can improve outcomes.
www.cell.com/cell/abstrac...
www.cell.com/cell/abstrac...